Chemotherapy-Induced Myelosuppression Treatment Market By Treatment Type (Granulocyte Colony-Stimulating Factors [G-CSFs], Erythropoiesis-Stimulating Agents [ESAs], Myeloprotective Agents, Thrombopoietic Agents [TPO-RAs], Blood & Platelet Transfusions, Other Supportive Treatments), By Myelosuppression Type (Chemotherapy-Induced Neutropenia, Chemotherapy-Induced Anemia, Chemotherapy-Induced Thrombocytopenia, Multilineage Myelosuppression), By End User (Hospitals, Oncology & Specialty Clinics, Cancer Treatment Centers), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Chemotherapy-Induced Myelosuppression Treatment Market: Powering the Next Era of Cancer Supportive Care

The Global Chemotherapy-Induced Myelosuppression Treatment Market was valued at USD 9.02 billion in 2025 and is projected to reach USD 12.52 billion by 2032, expanding at a CAGR of 4.8% during 2026–2032.

 

Chemotherapy-induced myelosuppression (CIM) is a major treatment-related complication because reductions in neutrophils, red blood cells and platelets can interrupt planned chemotherapy. Management includes G-CSFs for neutropenia, erythropoiesis-stimulating agents (ESAs) and red blood cell transfusions for anemia, platelet transfusions and selected thrombopoietic therapies for thrombocytopenia, and proactive bone marrow protection with trilaciclib in its approved setting. Treatment delays and chemotherapy dose reductions remain important commercial drivers because supportive care is increasingly evaluated by whether it enables patients to receive cancer therapy on schedule rather than simply correcting abnormal blood counts.

 

Trilaciclib (Cosela) is the first and only FDA-approved therapy designed specifically to reduce bone marrow suppression caused by chemotherapy. It is given intravenously before chemotherapy and helps protect the bone marrow so it can continue producing multiple types of blood cells. It is currently approved for use in adults with extensive-stage small cell lung cancer (ES-SCLC).

 

Demand for treatments like trilaciclib is closely linked to how often and how intensively chemotherapy is used, how long patients remain on treatment, and how frequently blood cell drops force doctors to delay or reduce cancer therapy. However, the market is not the same across all blood cell types. Neutropenia already has well-established preventive treatments, anemia therapies are more tightly controlled by clinical guidelines and reimbursement rules, while chemotherapy-induced thrombocytopenia (CIT) remains the area with the greatest unmet need and the most active drug development.

 

The burden of chemotherapy-induced myelosuppression is especially high in intensive cancers like ES-SCLC. A U.S. study found that nearly all treatment lines (98.6%) experienced at least one drop in blood cell counts, and 62.1% had severe (grade ≥3) events. In more than one-third of cases, multiple blood cell types were affected at the same time, showing the need for treatments that can support several blood cell lineages together. This is further supported by a 2025 study in China involving 7,505 patients across 52 hospitals, where 92% experienced CIM and 81.1% received G-CSF, confirming that managing low white blood cell counts remains the most common supportive-care approach in real-world practice.

 

Why Does G-CSF Remain the Largest Established Treatment Segment?

G-CSFs form the most established pharmacologic component of CIM management. Filgrastim and pegfilgrastim products stimulate neutrophil recovery and reduce the risk associated with chemotherapy-induced neutropenia. Short-acting filgrastim generally requires repeated administration, while long-acting pegfilgrastim enables once-per-cycle treatment, making administration frequency an important differentiator for oncology practices.

The 2026 ASCO guideline update continues to place colony-stimulating factors at the center of febrile-neutropenia prevention. Primary prophylaxis is recommended when the risk of febrile neutropenia from a chemotherapy regimen is approximately 20% or higher when an equally effective treatment with a lower risk is unavailable. Patient-specific factors can also justify prophylaxis at lower regimen-level risks. This guideline-backed prophylactic role creates recurring demand because G-CSF administration can accompany multiple chemotherapy cycles rather than being limited to treatment after severe neutropenia occurs.

Competition is increasingly shifting from clinical differentiation toward biologic pricing, hospital contracts and administration convenience. FDA's biosimilar portfolio includes Zarxio and Nivestym as filgrastim alternatives and multiple pegfilgrastim products including Fulphila, Udenyca, Ziextenzo, Nyvepria, Stimufend and others. FDA also approved additional products including Filkri in January 2026 and Ennumo in May 2026, showing that competition in the G-CSF category continues to expand.

Fresenius Kabi's Stimufend illustrates the competitive strategy in this segment. The company positioned the pegfilgrastim biosimilar as an oncology supportive-care product intended to reduce the duration of neutropenia and incidence of febrile neutropenia among patients receiving cytotoxic chemotherapy. Greater biosimilar availability improves treatment choice but also increases price competition for mature brands.

Amgen remains important through Neulasta, while newer and biosimilar pegfilgrastim products compete for the same chemotherapy-supportive-care accounts. Neulasta generated USD 435 million in global sales in 2025, compared with USD 431 million in 2024, representing approximately 1% annual growth. Its Q4 2025 sales reached USD 132 million, up 35% year over year. Amgen's established-product group, which includes Aranesp, Parsabiv and Neulasta, continued to generate substantial revenue, demonstrating the commercial scale that remains within mature hematologic supportive-care products despite rising biosimilar competition.

 

How Are Multilineage Protection and Thrombocytopenia Changing Treatment Opportunities?

Trilaciclib introduced a different treatment model by protecting bone marrow before chemotherapy instead of treating each cytopenia only after it develops. Cosela is administered before chemotherapy and is indicated in the United States to decrease chemotherapy-induced myelosuppression in adults receiving specified platinum/etoposide- or topotecan-containing regimens for ES-SCLC.

Its commercial relevance comes from multilineage protection. Patients with ES-SCLC can experience neutropenia, anemia and thrombocytopenia within the same chemotherapy course, creating requirements for growth factors, transfusions or chemotherapy modification. Preventing injury across several lineages therefore allows Cosela to compete on reduction of the broader supportive-care burden rather than on a single blood-cell endpoint.

G1 Therapeutics generated about USD 14.1 million from Cosela in Q1 2024 and was targeting USD 60–70 million in full-year sales before being acquired. In September 2024, Pharmacosmos acquired the company for around USD 405 million, adding Cosela to its blood disorder portfolio and signaling plans to expand the drug beyond the U.S., including into Europe. The deal highlights growing interest in bone marrow–protective therapies during chemotherapy. Following the acquisition, Pharmacosmos reported DKK 3.36 billion in revenue for fiscal 2024/25, up 40% year over year, with Cosela contributing to this growth.

The largest unmet need in chemotherapy-induced myelosuppression is chemotherapy-induced thrombocytopenia (CIT), as there is currently no FDA-approved therapy. Management is mainly supportive, including chemotherapy delays, dose reductions, platelet transfusions, and use of thrombopoietin receptor agonists, highlighting a clear gap for drugs that can maintain platelet counts and keep patients on schedule.

Amgen is advancing romiplostim (Nplate) in a Phase 3 trial for CIT. Nplate is already approved for other platelet disorders and generated USD 1.52 billion in 2025 sales, giving Amgen a strong commercial base as it explores expansion into CIT.

Avatrombopag (Doptelet, Sobi) is another key candidate, showing strong Phase 3 results in 2026 where 70% of patients achieved platelet recovery vs 17% on placebo in gastrointestinal cancers. The drug is already marketed for other thrombocytopenia indications and recorded SEK 1.63 billion in Q2 2026 sales, up 36% year over year, supporting its potential expansion into CIT if approved.

The CIT opportunity is particularly important because developers are increasingly using chemotherapy continuation as an endpoint. A therapy that allows full-dose, on-time chemotherapy can demonstrate value beyond platelet recovery and potentially reduce dependence on treatment delays and transfusions.

 

How Do Anemia Treatment and Reimbursement Shape Market Demand?

Chemotherapy-induced anemia represents another substantial treatment pathway, but ESA utilization is more restricted than G-CSF use. Epoetin alfa and darbepoetin alfa stimulate red blood cell production and can reduce transfusion requirements in selected patients receiving chemotherapy.

ASCO/ASH guidance recommends that ESAs may be offered to patients with chemotherapy-associated anemia when treatment is not curative in intent and hemoglobin has fallen below 10 g/dL. Red blood cell transfusion remains an alternative depending on severity and clinical circumstances. ESAs are not recommended for chemotherapy-associated anemia when cancer treatment is curative in intent.

Medicare reimbursement further defines the eligible population. CMS covers ESA treatment for anemia secondary to myelosuppressive anticancer chemotherapy under specified conditions, including hemoglobin below 10 g/dL or hematocrit below 30% before treatment. CMS does not cover prophylactic ESA use to prevent chemotherapy-induced anemia. These requirements prevent the anemia segment from expanding simply in proportion to the prevalence of low hemoglobin.

Competition also includes biosimilars. FDA lists Retacrit, an epoetin alfa biosimilar, among approved biosimilar products, creating additional price competition against established ESA brands. Amgen participates through Aranesp, while Pfizer's Retacrit gives the market a biosimilar alternative. Aranesp generated USD 1.39 billion in global sales in 2025, rising approximately 4% from USD 1.34 billion in 2024. International markets contributed USD 973 million, or about 70% of Aranesp's 2025 revenue, while U.S. sales reached USD 416 million.

The commercial value of anemia treatment therefore comes from reducing transfusion dependence in clearly eligible patients rather than broad prophylactic use. Treatment intent, hemoglobin level, duration of chemotherapy, response to therapy and reimbursement criteria all influence utilization. The combination of USD 1.39 billion in 2025 Aranesp sales and continued epoetin biosimilar competition illustrates why the anemia category remains commercially significant but more mature than emerging CIT-directed treatment.

 

How Are Regional Treatment Models Affecting Market Competition?

North America combines high use of physician-administered biologics with established Medicare Part B reimbursement for many supportive-care treatments. ASCO guidance also provides defined clinical pathways for G-CSF and ESA utilization, creating a structured market for chemotherapy supportive care. Biosimilar expansion is increasing competition within G-CSF and ESA categories, while CIT represents a potential new pharmacologic market if late-stage programs gain regulatory approval. North America accounted for an estimated 40–45% market share of the global chemotherapy-induced myelosuppression treatment market in 2025, translating to approximately USD 3.6–4.1 billion based on the global valuation of USD 9.02 billion, and is projected to expand broadly in line with the 4.8% global CAGR through 2032.

Europe has a stronger tender and procurement component. Pegfilgrastim and filgrastim biosimilars compete against reference biologics within national and hospital purchasing systems, favoring manufacturers able to combine reliable supply with competitive pricing. Fresenius Kabi's expansion of Stimufend and Sandoz's established filgrastim and pegfilgrastim portfolios reflect the importance of biosimilars in European oncology supportive care. FDA approvals for the same molecules also broaden international manufacturing scale and competition. Europe accounted for approximately 28% of the global market in 2025, equivalent to around USD 2.53 billion, and is projected to grow at a CAGR of about 4.5% during 2026–2032.

China represents an important treatment-volume opportunity. The 2025 ES-SCLC study involving 7,505 patients found CIM in 92.0% of patients and G-CSF use in 81.1%, demonstrating substantial supportive-care utilization within chemotherapy-intensive oncology. Cosela has also received approval in mainland China and is commercialized there through a partnership involving Simcere, extending multilineage myeloprotection beyond its initial U.S. market.

Asia-Pacific represents an estimated USD 2.7 billion opportunity in 2025, equivalent to nearly 30% of global demand, and is projected to expand at approximately 5.6% CAGR through 2032. High chemotherapy volumes in China, Japan and India and increasing availability of biosimilar G-CSFs support faster growth than the overall 4.8% market CAGR. Latin America represents about USD 0.9 billion, or close to 10% of the 2025 market, and is projected to grow at approximately 5.1% CAGR, supported by expanding oncology infrastructure and supportive-care access in Brazil, Mexico and other major markets.

Regional growth will differ by product class. Established G-CSFs and ESAs face continued biosimilar and procurement pressure, whereas newly approved myeloprotective or CIT therapies could create higher-value segments where fewer direct pharmacologic alternatives currently exist.

 

Which Companies Are Shaping the Competitive Landscape?

Amgen

Amgen has one of the broadest positions in chemotherapy supportive care through Neulasta (pegfilgrastim) for neutropenia and Aranesp (darbepoetin alfa) for anemia. The company is also developing Nplate (romiplostim) for CIT through the Phase 3 PROCLAIM program. Its portfolio therefore covers mature supportive-care markets while giving it exposure to the emerging platelet-support segment. In 2025, Aranesp generated USD 1.389 billion, Nplate USD 1.524 billion and Neulasta USD 435 million in global sales, placing the combined revenue of these three hematologic products at approximately USD 3.35 billion. Nplate grew 5%, Aranesp 4% and Neulasta 1% from 2024.

 

Pharmacosmos

Pharmacosmos became a key CIM company following its acquisition of G1 Therapeutics in September 2024 for approximately USD 405 million. Its principal CIM asset, Cosela (trilaciclib), offers proactive multilineage myeloprotection before specified chemotherapy regimens in ES-SCLC. The company's opportunity depends on increasing utilization in its established indication and expanding the product geographically. Pharmacosmos' revenue increased 40% to DKK 3.362 billion in fiscal 2024/25 from DKK 2.403 billion in the prior year, with the G1 Therapeutics acquisition and Cosela integration strengthening its blood-disorder portfolio.

 

Sandoz

Sandoz competes in neutropenia management through Zarxio (filgrastim-sndz) and Ziextenzo (pegfilgrastim-bmez). Both are part of the expanding biosimilar market that is reducing dependence on reference biologics and increasing price competition in G-CSF therapy. FDA identifies both products within its approved biosimilar portfolio.

 

Fresenius Kabi

Fresenius Kabi participates through Stimufend (pegfilgrastim-fpgk). Its strategy centers on offering a biosimilar alternative for patients receiving myelosuppressive chemotherapy, strengthening competition in hospital and oncology-clinic accounts.

 

Pfizer

Pfizer has a presence across more than one supportive-care category through products including Nivestym (filgrastim-aafi) and Retacrit (epoetin alfa-epbx). FDA's biosimilar listings confirm their positions as alternatives to reference filgrastim and epoetin products. This gives Pfizer exposure to both chemotherapy-induced neutropenia and eligible chemotherapy-associated anemia.

 

Swedish Orphan Biovitrum (Sobi)

Sobi markets Doptelet (avatrombopag) for approved thrombocytopenia indications and is strategically relevant to the emerging CIT opportunity because avatrombopag produced positive results in the 2026 ACT-GI study. Successful regulatory expansion into CIT would give the company access to a supportive-care area with no currently approved U.S. pharmacologic treatment. Sobi reported SEK 28.24 billion in total revenue for 2025, increasing 15% at constant exchange rates, while Doptelet remained one of the company's major growth products. In Q2 2026, Doptelet generated SEK 1.628 billion, up 36% at constant exchange rates, highlighting the scale of Sobi's existing thrombocytopenia franchise.

 

Other G-CSF Competitors

The competitive field also includes companies associated with Udenyca, Fulphila, Nyvepria, Fylnetra, Releuko, Nypozi, Filkri, Armlupeg and Ennumo, among other FDA-approved filgrastim and pegfilgrastim biosimilars. The growing number of alternatives makes G-CSF increasingly volume- and contract-driven, while innovation is shifting toward multilineage protection and platelet recovery.

 

Analyst Perspective

The chemotherapy-induced myelosuppression market is shifting from treating individual blood count drops to keeping patients on full chemotherapy schedules, which is becoming the key value driver.

G-CSF therapies remain the backbone of treatment due to strong guideline support for preventing febrile neutropenia. However, rising biosimilar competition from multiple pegfilgrastim and filgrastim versions approved by FDA is putting pressure on prices, so growth is now driven more by treatment volume and usage across cancer centers than pricing power. Amgen's USD 435 million in 2025 Neulasta revenue and modest 1% annual growth reflect this mature competitive profile.

Anemia treatments (ESAs) remain steady but limited. Their use is restricted by hemoglobin thresholds and payer rules, which keeps the market stable but prevents major expansion. Biosimilars like Retacrit also add pricing pressure. Aranesp nevertheless generated USD 1.39 billion in 2025 revenue, up 4%, showing that eligible chemotherapy-associated anemia and other covered anemia indications continue to support a large established ESA business.

The biggest growth opportunity is chemotherapy-induced thrombocytopenia (CIT), where no FDA-approved therapy currently exists. Late-stage development of Amgen's romiplostim and positive 2026 data for avatrombopag, with 70% response versus 17% for placebo in the ACT-GI study, highlight strong pipeline momentum. Nplate's USD 1.52 billion in 2025 global sales and Doptelet's SEK 1.63 billion Q2 2026 sales, up 36% at constant exchange rates, also show that both companies already operate sizeable thrombocytopenia franchises that could support CIT expansion if clinical and regulatory milestones are achieved.

A second emerging area is multilineage protection, led by Cosela (trilaciclib), which is already approved in ES-SCLC and acquired by Pharmacosmos in an approximately USD 405 million deal, signaling long-term interest in broader bone marrow protection strategies. Pharmacosmos' 40% revenue increase to DKK 3.36 billion in fiscal 2024/25 further expands the commercial resources behind the product.

Overall, future competition will focus less on correcting low blood counts and more on preventing chemotherapy delays, dose reductions, and transfusions, making treatment continuity the key success metric in CIM care. With the overall market expected to grow from USD 9.02 billion in 2025 to USD 12.52 billion by 2032 at a 4.8% CAGR, the faster opportunity is likely to come from thrombocytopenia-directed and multilineage approaches, while G-CSFs and ESAs remain the established revenue base of the market.

 

Chemotherapy-Induced Myelosuppression Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 9.02 Billion
Revenue Forecast in 2032	USD 12.52 Billion
Overall Growth Rate	CAGR of 4.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Myelosuppression Type, By End User, By Geography
By Treatment Type	Granulocyte Colony-Stimulating Factors [G-CSFs], Erythropoiesis-Stimulating Agents [ESAs], Myeloprotective Agents, Thrombopoietic Agents [TPO-RAs], Blood & Platelet Transfusions, Other Supportive Treatments
By Myelosuppression Type	Chemotherapy-Induced Neutropenia, Chemotherapy-Induced Anemia, Chemotherapy-Induced Thrombocytopenia, Multilineage Myelosuppression
By End User	Hospitals, Oncology & Specialty Clinics, Cancer Treatment Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing chemotherapy utilization, rising incidence of treatment-related blood cell disorders, growing adoption of G-CSF supportive therapies, demand for maintaining chemotherapy dose intensity, unmet need for chemotherapy-induced thrombocytopenia treatments, expansion of multilineage bone marrow protection approaches
Customization Option	Available upon request